Literature DB >> 25385562

A report of a successfully treated case of ABPA in an HIV-infected individual.

Valliappan Muthu1, Ritesh Agarwal1.   

Abstract

Aspergillus fumigatus is a ubiquitous fungus responsible for a variety of pulmonary diseases, ranging from infection of a pre-existing cavity as in aspergilloma to highly invasive disease in immunocompromised hosts. Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity response mounted against antigens of A. fumigatus manifesting as poorly controlled asthma and bronchiectasis. Although ABPA is not uncommon, occurrence of ABPA in HIV-affected individuals is distinctly rare. We describe the occurrence of ABPA in a 35-year-old woman with poorly controlled asthma since childhood and HIV-1 infection of 11 years duration. This is the second documented case of ABPA in a HIV-affected individual, and the first reported case to be successfully managed with antifungal therapy alone. We also discuss the complex management issues involved in treating ABPA in HIV-affected individuals. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25385562      PMCID: PMC4225263          DOI: 10.1136/bcr-2014-206236

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA?

Authors:  Ritesh Agarwal; Basanta Hazarika; Dheeraj Gupta; Ashutosh N Aggarwal; Arunaloke Chakrabarti; Surinder K Jindal
Journal:  Med Mycol       Date:  2010-11       Impact factor: 4.076

2.  Allergic bronchopulmonary aspergillosis in an HIV-infected individual.

Authors:  M Jain
Journal:  Allergy Asthma Proc       Date:  2000 Nov-Dec       Impact factor: 2.587

Review 3.  Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.

Authors:  R Agarwal; A Chakrabarti; A Shah; D Gupta; J F Meis; R Guleria; R Moss; D W Denning
Journal:  Clin Exp Allergy       Date:  2013-08       Impact factor: 5.018

4.  High attenuation mucoid impaction in allergic bronchopulmonary aspergillosis.

Authors:  Ritesh Agarwal
Journal:  World J Radiol       Date:  2010-01-28

Review 5.  Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.

Authors:  David A Stevens; Richard B Moss; Viswanath P Kurup; Alan P Knutsen; Paul Greenberger; Marc A Judson; David W Denning; Reto Crameri; Alan S Brody; Michael Light; Marianne Skov; William Maish; Gianni Mastella
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079

6.  Management of pulmonary aspergillosis in AIDS: an emerging clinical problem.

Authors:  J J Keating; T Rogers; M Petrou; J D Cartledge; D Woodrow; M Nelson; D A Hawkins; B G Gazzard
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

Review 7.  Immunologic abnormalities in the acquired immunodeficiency syndrome.

Authors:  H C Lane; A S Fauci
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

Review 8.  Allergic bronchopulmonary aspergillosis.

Authors:  Ritesh Agarwal
Journal:  Chest       Date:  2009-03       Impact factor: 9.410

Review 9.  Role of inhaled amphotericin in allergic bronchopulmonary aspergillosis.

Authors:  I S Sehgal; R Agarwal
Journal:  J Postgrad Med       Date:  2014 Jan-Mar       Impact factor: 1.476

10.  Pulmonary aspergillosis in the acquired immunodeficiency syndrome.

Authors:  D W Denning; S E Follansbee; M Scolaro; S Norris; H Edelstein; D A Stevens
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

View more
  2 in total

Review 1.  Allergic bronchopulmonary aspergillosis in an adult with Kartagener syndrome.

Authors:  Inderpaul Singh Sehgal; Sahajal Dhooria; Amanjit Bal; Ritesh Agarwal
Journal:  BMJ Case Rep       Date:  2015-08-06

2.  Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis: Case Report and Review of Literature.

Authors:  Panagis Galiatsatos; Michael T Melia; Leann L Silhan
Journal:  Open Forum Infect Dis       Date:  2016-06-20       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.